Latest Headlines

Latest Headlines

Acadia soars as FDA green-lights a late-stage shortcut for Parkinson's drug

Shares of Acadia Pharmaceuticals shot up 44% this morning after the San Diego-based biotech announced that the FDA had signed off on a new timeline allowing the biotech to skip a confirmatory late-stage study for their Parkinson's psychosis drug pimavanserin and move straight ahead with a new drug application after tying up some loose ends in the clinic.

Bullish Acadia surges on PhIII data for Parkinson's drug

Shares of San Diego-based Acadia Pharmaceuticals surged 28% this morning after the biotech spelled out some of its Phase III data on pimavanserin, its experimental therapy for treating psychosis in Parkinson's patients.

UPDATED: Acadia soars after Parkinson's drug makes a comeback with promising PhIII

Acadia Pharmaceuticals heralded positive pivotal data for its late-stage Parkinson's contender pimavanserin this morning, marking a big turnaround or a program that had spurred more doubt than hope when a similar Phase III effort was scuttled by a big placebo effect back in 2009.

Acadia, Biovail end Parkinson's drug deal

Acadia Pharmaceuticals and Biovail, a subsidiary of Valeant Pharmaceuticals, said this morning that they have ended the collaboration agreement on pimavanserin, a drug for Parkinson's. Last year the

Acadia shares tank after Parkinson's drug flunks Phase III

The placebo effect has scuttled the late-stage study of an experimental Parkinson's therapy being co-developed by Acadia Pharmaceuticals and Biovail, and the news immediately triggered a meltdown in

Acadia shares up on pimavanserin speculation

Speculation on as yet unreleased data from a late stage trial of Acadia Pharmaceuticals' experimental drug for Parkinson's disease psychosis has fueled unexpectedly heavy activity among investors on

Acadia inks $395 million development deal

Acadia Pharmaceuticals will pocket $30 million upfront and stands to earn another $365 million in milestones from Biovail as they pursue an approval for a late-stage drug designed to treat

Acadia slashes staff, focuses on four candidates

Acadia Pharmaceuticals will slash funding for early-stage development as it lays off 65 employees and concentrates on the advancement of its four most promising programs. Acadia had 143 staffers at

Acadia shares plunge on mid-stage trial failure

Shares of Acadia Pharmaceuticals went into free fall this morning after the company announced that one of its schizophrenia drug candidates failed a mid-stage trial. Researchers said that ACP-104 was